(King of Prussia, PA; St. Louis, MO; Feb. 17, 2015) - Theorem Clinical Research, a prominent global contract research organization, and Biomedical Systems, a leading provider of comprehensive centralized diagnostic services, have formed a strategic partnership to expand the suite of services available to clients worldwide.
“Theorem’s business strategy is to offer our clients the very best available services in every research area,” said John Potthoff, Theorem president and CEO. “Biomedical Systems is one of the true pioneers in our industry, supervising breakthrough research innovations in centralized cardiac safety, pulmonary function, imaging, scientific affairs and electronic clinical outcome assessment (eCOA). The company’s broad range of capabilities and global scale are a complement to Theorem studies being conducted around the world.”
Headquartered in St. Louis, Biomedical Systems also has a European office in Brussels, with logistical support facilities in Japan and India and investigative sites in almost 100 countries. Theorem Clinical Research has offices in more than 30 countries worldwide, offering deep expertise in a broad range of therapeutic areas and all phases of development.
“The right strategic alliance strengthens both companies, empowering us both to offer enhanced services to our clients,” said Tim Barrett, CEO of Biomedical Systems. “We believe this alliance with Theorem creates a synergy that will be a benefit to all.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.